Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

“…In view of the early luteolysis that occurs after GnRH agonist trigger, it may be postulated that circulating VEGF levels will be significantly lower in the luteal phase, which may be the pathophysiological basis for the significantly lower rate of OHSS reported in several studies (1,2,21,22). However, we did not show any significant differences in lutealphase VEGF levels between patients triggered with either GnRH agonist or hCG.…”

Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders

“…Although there have been several strategies proposed, GnRH agonist (GnRHa) to induce oocyte maturation has been shown to be the most effective method to reduce the risk of OHSS (2)(3)(4). Studies have shown lower conception and higher miscarriage rates in patients triggered with GnRHa compared with hCG (5,6).…”

Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist

“…In several studies, the use of a gonadotropin-releasing hormone (GnRH) antagonist protocol coupled with a GnRH agonist for final oocyte maturation has been shown to prevent occurrence of this condition (1)(2)(3)(4). Despite this clear benefit, physicians are apprehensive to use a GnRH-agonist trigger because previous studies in normal responders have demonstrated lower pregnancy rates after its use (5,6).…”